Roshawn Blunt, Brand Insights Contributor, Managing Director of 1798, a Fingerpaint company
Advertisement
We’re 220+ strong, fully independent, and ready to handle any healthcare marketing challenge you care to throw at us.
Articles by Roshawn Blunt, Brand Insights Contributor, Managing Director of 1798, a Fingerpaint company
Why it’s important to integrate patient assistance programs for cell and gene therapies into the overall clinical development plan.
Solving Access Challenges in Today’s Market
ByAndy Pyfer, Brand Insights Contributor, Partner, Fingerpaint,Roshawn Blunt, Brand Insights Contributor, Managing Director of 1798, a Fingerpaint company
Published: | Updated:
New drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.
Advertisement
Latest Updated Articles
- Solving Access Challenges in Today’s Market
Published: April 30th 2020 | Updated: December 20th 2020
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Pharmaceutical Executive Daily: FDA Approves Hernexeos
3
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
4
FDA Approves Hernexeos Under National Priority Voucher Program
5